COLOGNE, Germany--(BUSINESS WIRE)--Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which Axiogenesis obtains worldwide access to the extensive portfolio of induced pluripotent stem cell (“iPSC”) technology for iPSC-derived cardiomyocytes and other cell types, pioneered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application (CiRA) at the University of Kyoto, Japan.
